The Prevalence of Behçet's Disease in a Thrombosis Clinic

Overview

Journal Mediterr J Rheumatol

Specialty Rheumatology

Date 2023 May 24

PMID 37223605

Authors

Mira Merashli

Paul Rj Ames

Affiliations

Soon will be listed here.

Abstract

Background: the prevalence of venous thromboembolism (VTE) in Behcet's disease (BD) is around 40%, though recognition of BD in a thrombosis clinic has been poorly addressed.

Objective: to evaluate the prevalence of signs and symptoms leading to the diagnosis of BD in a thrombosis clinic compared to patients attending a general haematology clinic and to healthy controls. Design: cross-sectional case-double control anonymous questionnaire survey. Participants: consecutive patients with spontaneous VTE (n=97) attending a thrombosis clinic, consecutive patients from a general haematology (GH) clinic (n=89) and controls (CTR).

Results: BD was diagnosed in 1.03% of VTE participants, in 2.2% of GH participants and in 1.2% of healthy CTR. Exhaustion was more common reported in participants from the VTE group (15.6%) than in those from the GH group (10.3%) and from the healthy CTR (3%) (p=0.06); the sum of signs and symptoms of BD clustered in the VTE group (89.5%) compared to the GH (72.4%) and the CTR (59.7%) (p<0.0001).

Conclusions: BD may be diagnosed in 1 every 100 patients with VTE attending a thrombosis clinic and in 2 every 100 patients attending a GH clinic: awareness must be raised not to under-diagnose or misdiagnose BD in these settings as management of VTE in BD deviates from the norm.

References

Kidd D . The prevalence of Behçet's syndrome and its neurological complications in Hertfordshire, U.K. Adv Exp Med Biol. 2003; 528:95-7. DOI: 10.1007/0-306-48382-3_19. View

Onder M, Gurer M . The multiple faces of Behçet's disease and its aetiological factors. J Eur Acad Dermatol Venereol. 2001; 15(2):126-36. DOI: 10.1046/j.1468-3083.2001.00251.x. View

Desbois A, Wechsler B, Cluzel P, Helft G, Boutin D, Piette J . [Cardiovascular involvement in Behçet's disease]. Rev Med Interne. 2014; 35(2):103-11. DOI: 10.1016/j.revmed.2013.12.002. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

Busuttil A, Lim C, Davies A . Post Thrombotic Syndrome. Adv Exp Med Biol. 2016; 906:363-375. DOI: 10.1007/5584_2016_126. View

Lukas P, Krummenacher R, Demarmels Biasiutti F, Begre S, Znoj H, von Kanel R . Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic event. Thromb Haemost. 2009; 102(6):1219-26. DOI: 10.1160/TH09-05-0316. View

Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M, Yazganoglu K, Disci R, Erzengin D . Vascular involvement in Behçet's disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006; 45(8):919-21. DOI: 10.1111/j.1365-4632.2006.02832.x. View

. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2013; 28(3):338-47. DOI: 10.1111/jdv.12107. View

Kaklamani V, Vaiopoulos G, Kaklamanis P . Behçet's Disease. Semin Arthritis Rheum. 1998; 27(4):197-217. DOI: 10.1016/s0049-0172(98)80001-2. View

10.

Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O . Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008; 58(12):3951-9. DOI: 10.1002/art.24149. View

11.

Ames P, Steuer A, Pap A, DENMAN A . Thrombosis in Behçet's disease: a retrospective survey from a single UK centre. Rheumatology (Oxford). 2001; 40(6):652-5. DOI: 10.1093/rheumatology/40.6.652. View

12.

Desbois A, Wechsler B, Resche-Rigon M, Piette J, Le Thi Huong D, Amoura Z . Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum. 2012; 64(8):2753-60. DOI: 10.1002/art.34450. View